Results—1
| . | IFN + PUVA (n = 40) . | IFN + Acitretin (n = 42) . |
|---|---|---|
| CR | ||
| Stage I | 26/31 (83.9) | 16/33 (48.5) |
| Stage II | 2/9 (22.2) | 0/9 |
| All stages | 28/40 (70.0)* | 16/42 (38.1) |
| PR | ||
| Stage I | 1/31 (3.2) | 5/33 (15.6) |
| Stage II | 3/9 (33.3) | 4/9 (44.4) |
| All stages | 4/40 (10.0) | 9/42 (21.4) |
| Minor response, all stages | 3/40 (7.5) | 8/42 (19.0) |
| No change, all stages | 4/40 (10.0) | 4/42 (9.5) |
| Progression, all stages | 0 | 1/42 (2.4) |
| Missing data | 1 | 4 |
| Time to CR (wk) | ||
| Median | 18.6† | 21.8 |
| Range | 4.4-45.6 | 7.1-63.1 |
| Time to response (wk) | ||
| Median | 10.9‡ | 12.6 |
| Range | 3.3-26.6 | 3-63.1 |
| . | IFN + PUVA (n = 40) . | IFN + Acitretin (n = 42) . |
|---|---|---|
| CR | ||
| Stage I | 26/31 (83.9) | 16/33 (48.5) |
| Stage II | 2/9 (22.2) | 0/9 |
| All stages | 28/40 (70.0)* | 16/42 (38.1) |
| PR | ||
| Stage I | 1/31 (3.2) | 5/33 (15.6) |
| Stage II | 3/9 (33.3) | 4/9 (44.4) |
| All stages | 4/40 (10.0) | 9/42 (21.4) |
| Minor response, all stages | 3/40 (7.5) | 8/42 (19.0) |
| No change, all stages | 4/40 (10.0) | 4/42 (9.5) |
| Progression, all stages | 0 | 1/42 (2.4) |
| Missing data | 1 | 4 |
| Time to CR (wk) | ||
| Median | 18.6† | 21.8 |
| Range | 4.4-45.6 | 7.1-63.1 |
| Time to response (wk) | ||
| Median | 10.9‡ | 12.6 |
| Range | 3.3-26.6 | 3-63.1 |